Laurion Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Laurion Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,250	Closed	-$525K	–	910
2021 Q2	$525K	Buy	+3,250	New	+$522K	﹤0.01%	505
2019 Q3	–	Sell	-26,545	Closed	-$2.73M	–	1339
2019 Q2	$2.73M	Buy	26,545 +17,240	+185%	+$1.34M	0.03%	346
2019 Q1	$682K	Buy	+9,305	New	+$633K	0.01%	582
2018 Q2	–	Sell	-34,802	Closed	-$1.07M	–	1648
2018 Q1	$1.07M	Buy	+34,802	New	+$966K	0.01%	825

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Laurion Capital Management's MRTX Position: Q3 2021 in Review

Laurion Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 3,250 shares — an estimated $525K sold.

Laurion Capital Management first reported a position in MRTX in Q1 2018 and held it in 4 quarters. The position peaked at $2.73M in Q2 2019. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

Laurion Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Laurion Capital Management sold 3,250 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $525K.
Laurion Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 4 quarters.
Laurion Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.73M in Q2 2019.
238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Laurion Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.